Practice with mock tests, learn from structured notes, and get your questions answered by a global forensic community, all in one place.
Distinguishing menstrual blood from peripheral (venous or arterial) blood is a forensic challenge with direct implications for sexual assault and injury investigations. This topic covers fibrinolytic activity, matrix metalloprotease MMP-10, D-dimer, and the current limitations of available assays.
Last updated:
Blood is blood to a luminol spray or a haemoglobin peroxidase test. But in forensic casework, the source of blood matters enormously. A stain that looks like evidence of violence might be menstrual blood shed during consensual sex. A suspect who says the blood on their clothing came from their partner's menstruation may be telling the truth, or may not be. The forensic serologist needs a way to tell the difference, and for most of forensic science's history, no reliable method existed.
The biochemical difference between menstrual and peripheral blood is real and well-characterized. Menstrual blood does not clot. It contains high levels of fibrinolytic enzymes, including tissue plasminogen activator released by the shedding endometrium, that actively break down fibrin. It also contains matrix metalloproteases involved in endometrial remodelling that are not present in circulating blood. Measuring these markers is the basis for emerging forensic differentiation methods.
The honest position as of current practice is that no commercial, fully validated assay for routine casework exists. Several research groups have published promising results with MMP-10, D-dimer, and multi-marker mRNA approaches. Understanding what these tests measure, and where they fall short, is necessary both for practitioners evaluating new methods and for anyone interpreting literature on the topic.
One clots, one does not: the starting point for differentiation.
Peripheral blood (venous, arterial, or capillary) clots on exposure to air through the coagulation cascade, forming a fibrin mesh that traps red cells. Menstrual blood does not. The endometrium produces prostaglandins that induce vasoconstriction and smooth muscle contraction during shedding, but it also releases high concentrations of tPA and other fibrinolytic agents that prevent stable clot formation in the uterine cavity, allowing the lining to be expelled as fluid rather than coagulated material.
This fundamental difference in haemostatic behaviour has been the basis for forensic differentiation attempts since the 1980s. Early methods used fibrin clot formation tests: expose the stain extract to conditions that promote clotting and see if a clot forms. Peripheral blood forms a firm clot; menstrual blood forms none or a fragile, rapidly lysed one. The limitation is that old stains have degraded proteins that affect coagulation regardless of source.
An enzyme of tissue remodelling that has no business being in peripheral blood.
The MMP family of enzymes remodels the extracellular matrix. MMP-10, specifically, is involved in degrading fibronectin and laminin during endometrial breakdown. Research by groups including Bauer and colleagues demonstrated that MMP-10 concentrations in menstrual blood are many times higher than in peripheral blood from the same donors, and that an ELISA assay could detect this difference in stain extracts.
The challenge for forensic application is stability. MMP-10 is a protein and degrades over time in dried stains, with degradation accelerated by heat and UV exposure. Studies using fresh stains showed good discrimination, but performance on aged stains was more variable. A stain deposited weeks or months before examination may give an intermediate or negative result even from genuine menstrual blood.
Measuring the aftermath of active fibrinolysis.
D-dimer is generated when cross-linked fibrin is cleaved by plasmin. In peripheral blood that has not undergone significant fibrinolytic activity, D-dimer levels are low. In menstrual blood, where high tPA activity drives active fibrinolysis throughout the shedding period, D-dimer accumulates to much higher concentrations. Clinical D-dimer tests (used widely in medicine to exclude pulmonary embolism) have been adapted for application to forensic stain extracts.
| Marker | Elevated in | Test type | Main limitation for casework |
|---|---|---|---|
| tPA activity | Menstrual blood | Functional enzyme assay | Enzyme activity degrades rapidly in dried stains |
| D-dimer | Menstrual blood | Clinical immunoassay adapted for stains | Degradation; age and heat reduce levels |
| MMP-10 protein | Menstrual blood | ELISA (research); not yet commercial forensic kit | Protein stability in aged stains; cycle-phase variation |
| MMP-10 mRNA | Menstrual blood | RT-PCR-based mRNA profiling | mRNA degrades faster than protein; requires cold chain |
| Fibrin clot test | Peripheral blood clots; menstrual does not | Functional coagulation test | Degraded stain extracts may fail to clot regardless of source |
Studies have shown D-dimer concentrations in menstrual stain extracts are consistently and significantly higher than in peripheral blood stains of the same age, at least for fresh to moderately aged stains. An immunoturbidimetric or ELISA D-dimer assay on a stain extract provides a quantitative result that can be compared with a threshold, rather than a simple positive-or-negative band.
Tissue-specific transcripts survive in dried blood long enough to be useful.
The mRNA approach to body fluid identification asks which genes are being actively transcribed in the cells present in a stain. Endometrial cells shed during menstruation express transcripts of genes involved in the menstrual cycle: LEFTY2 (left-right determination factor 2, expressed in endometrium during the secretory phase), GLYCAM1 (endometrial surface glycoprotein), and MMP-10 mRNA, among others. These transcripts are detectable by RT-PCR in menstrual blood but not in peripheral blood.
The advantage of mRNA profiling is selectivity: a transcript that is specifically expressed in the endometrium provides a direct cellular origin marker without relying on non-specific enzymes or degradation products. The disadvantage is lability. RNA degrades more rapidly than DNA or protein, and mRNA profiling of stains older than a few days to weeks gives increasingly poor results.
Three case contexts where getting this wrong changes the investigation.
The distinction between menstrual and peripheral blood is not an academic exercise. Three main case types turn on it.
Critically, the DNA in menstrual blood is the same DNA as peripheral blood from the same individual. A DNA match to the victim or suspect does not tell the analyst which type of blood it is. Body-fluid characterisation must precede or accompany DNA profiling to provide the full interpretive picture.
What the field is waiting for before this becomes routine.
Several research groups have published proof-of-concept results for MMP-10, D-dimer, mRNA markers, and combined panels. The gap between a research publication and a validated forensic assay is significant. Full validation requires testing on a large number of donors across a range of hormonal states, ages, cycle phases, and health conditions, followed by assessment of performance on aged, contaminated, and environmentally stressed stains, and then accreditation under laboratory quality standards.
As of current practice, the field position is that a trained analyst can offer a provisional assessment using a combination of fibrinolytic activity tests and, where available, MMP-10 or D-dimer assays, but the result must be reported with clear qualification that the distinction is not yet supported by a fully validated commercial method. The interpretation carries less weight than, say, a positive RSID-Semen result, which has extensive validation data behind it.
What is the primary reason menstrual blood does not clot, unlike peripheral blood?
Test yourself on Forensic Serology with free, timed mocks.
Practice Forensic Serology questionsSpotted an error in this page? Report a correction or read our editorial standards.